Recall: AmEx Pharmacy Bevacizumab 1.25mg/0.05mL 31G Injectable
On 2019-04-29, the FDA announced that AmEx Pharmacy is conducting a recall on Bevacizumab 1.25mg/0.05mL 31G Injectable due to a possible . The recalled products were sold under the brand name(s) AmEx Pharmacy during an unspecified time period throughout the regions shown in the map below.
In recent months, there have been 1 drugs recalls due to potential defect, including epipen (epinephrine injection, usp) and epipen jr (epinephrine injection, usp) auto-injectors, glucagon [rdna origin] for injection and more. Additionally, there have been 29 drug and medical device recalls due to other health hazards as well as 78 food recalls.
Company Contact Information:
Name: AmEx Pharmacy
Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.
Detailed Recall Information
Regions Where Sold: Nationwide
Product Description: Bevacizumab 1.25mg/0.05mL 31G Injectable
Brand Name(s): AmEx Pharmacy
Reason for Recall: Defect
Official Recall Date: 2019-04-29
Additional information provided by the FDA.gov:
AmEx Pharmacy is voluntarily recalling one Lot of Bevacizumab 1.25mg/0.05mL 31G Injectable to the consumer/user level. The Monoject Syringe of this product may become difficult to express, and when additional force is applied, while the needle is in the eye, may cause injury to the patient. Read More.
More information may be available at FDA.gov
Latest Safety Recalls
Select image for details, including additional styles.
Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.